• Applied Biosystems (Carlsbad, California) reported the expansion of its portfolio of capillary electrophoresis sequencing systems with the introduction of two new lines of genetic analyzers. The 3500 Dx Series is intended for clinical use and will initially be launched in specific countries within the European Union. Both platforms will provide advancements in CE sequencing systems, setting significant new standards for throughput, data quality and ease of use. The 3500 Dx Series Genetic Analyzers are intended for use by trained operators in the analysis of human DNA or RNA for the detection of genetic changes that may lead to disease presence or susceptibility.

• Boston Scientific (Natick, Massachusetts) has received FDA clearance to market its SpyScope access and delivery catheter for diagnostic and therapeutic applications during endoscopic procedures in the pancreatico-biliary system. The SpyScope catheter is used in conjunction with the SpyGlass direct visualization system. Previously available for use only in the bile and hepatic ducts, the SpyGlass System can now be used to guide visualization and accessory devices throughout the entire pancreatico-biliary system, enabling physicians to diagnose and treat pancreatic cancer or pre-cancerous tissues.The SpyGlass direct visualization system is a single-operator system developed to overcome the limitations of traditional cholangioscopy systems and reduce the need for exploratory surgery. The SpyGlass is designed to enable physicians to directly visualize the target site, obtain a diagnostic tissue sample with the disposable SpyBite Biopsy Forceps, and deliver therapies such as laser and EHL.

• Exiqon Diagnostics (Tustin, California) said it now offers KRAS Mutation Analysis through its CLIA laboratory in California. Cancer treating physicians now have access to this critical test for their advanced stage colorectal and non-small cell lung cancer patients who are candidates for anti-EGFR therapy. Recent studies strongly correlate the presence of KRAS mutations in colorectal cancer patients with lack of response to cetuximab and panitumumab, shorter progression-free survival (PFS) and shorter overall survival. Studies performed in NSCLC have shown that mutations in the KRAS gene are strongly predictive of resistance to tyrosine kinase inhibitors such as gefitinib and eroltinib.

• GE Healthcare (Chalfont St. Giles, UK) reported the launch of IN Cell Investigator v1.5 software, the latest addition to the Investigator range of image analysis tools for automated high-content analysis of live and fixed cells. The new features of IN Cell Investigator v1.5 facilitate – Whole Well Analysis: the generation of a panoramic image through image stitching of overlapping images enables the analysis of whole wells, larger cell populations and model organisms; Texture Analysis, for deeper insight into results, particularly for toxicology and cell cycle; 3D-angiogenic tubules formation analysis; and Cell feature tracking to get a temporal perspective of cellular processes.

• Interson (Pleasanton, California) reported the launch of the SeeMore USB Ultrasound Imaging probe. SeeMore probes plug directly into the USB port of a laptop, netbook, or desktop computer. General purpose and specialty probes are available for a wide range of clinical applications including: abdominal, OB/GYN, bladder scanning, emergency, vascular access, small parts, musculo-skeletal, nerve blocks, endocavity (prostate, transvaginal) and more, and range in frequency from 3.5 MHz to 24 MHz.

• Qiagen (Venlo, the Netherlands) reported the launch of a novel product for extraction of free circulating fragments of tumor- and fetal-derived nucleic acids as well as viral nucleic acids in human blood. Scientists consider these DNA and RNA fragments to have great potential for the highly sensitive and non-invasive diagnosis of a wide range of diseases, including congenital disorders, malignancies such as colon and lung cancer, and infections. The QIAamp Circulating Nucleic Acid Kit enables the isolation and purification of all types and all sizes of nucleic acids from large-scale plasma and serum samples – and thereby enables unprecedented yields of the isolated molecules and the highest sensitivity of downstream applications. This facilitates the molecular detection of viral infections, where extraction of even the scarcest traces of genetic material is a key requirement for reliable results.